Theravance Biopharma (TBPH)
(Delayed Data from NSDQ)
$8.74 USD
-0.11 (-1.24%)
Updated May 20, 2022 04:00 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Detailed Estimates
Estimates
Exp Earnings Date | 8/2/22 |
---|---|
Current Quarter | 0.08 |
EPS Last Quarter | -0.24 |
Last EPS Surprise | -100.00% |
ABR | 3.08 |
Earnings ESP
|
2.00% |
---|---|
Current Year | 0.06 |
Next Year | 0.26 |
EPS (TTM) | -1.95 |
P/E (F1) | 145.67 |
Sales Estimates
Current Qtr (6/2022) |
Next Qtr (9/2022) |
Current Year (12/2022) |
Next Year (12/2023) |
|
---|---|---|---|---|
Zacks Consensus Estimate | 18.43M | 21.76M | 98.45M | 87.33M |
# of Estimates | 3 | 3 | 2 | 3 |
High Estimate | 22.50M | 30.00M | 104.79M | 123.15M |
Low Estimate | 14.88M | 15.45M | 92.11M | 68.56M |
Year ago Sales | 12.91M | 13.19M | 55.31M | 98.45M |
Year over Year Growth Est. | 42.73% | 65.00% | 78.00% | -11.30% |
Earnings Estimates
Current Qtr (6/2022) |
Next Qtr (9/2022) |
Current Year (12/2022) |
Next Year (12/2023) |
|
---|---|---|---|---|
Zacks Consensus Estimate | 0.08 | 0.23 | 0.06 | 0.26 |
# of Estimates | 3 | 2 | 4 | 4 |
Most Recent Consensus | NA | NA | NA | NA |
High Estimate | 0.17 | 0.31 | 0.82 | 0.97 |
Low Estimate | 0.00 | 0.14 | -1.07 | -1.15 |
Year ago EPS | -0.80 | -0.48 | -2.87 | 0.06 |
Year over Year Growth Est. | 110.00% | 147.92% | 102.09% | 333.33% |
Agreement - Estimate Revisions
Current Qtr (6/2022) |
Next Qtr (9/2022) |
Current Year (12/2022) |
Next Year (12/2023) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 0 | 0 | 1 | 1 |
Up Last 60 Days | 0 | 0 | 1 | 1 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 0 | 0 | 2 | 1 |
Down Last 60 Days | 0 | 0 | 2 | 1 |
Magnitude - Consensus Estimate Trend
Current Qtr (6/2022) |
Next Qtr (9/2022) |
Current Year (12/2022) |
Next Year (12/2023) |
|
---|---|---|---|---|
Current | 0.08 | 0.23 | 0.06 | 0.26 |
7 Days Ago | 0.07 | 0.25 | 0.06 | 0.47 |
30 Days Ago | 0.11 | 0.30 | 0.54 | 0.78 |
60 Days Ago | 0.11 | 0.30 | 0.55 | 0.82 |
90 Days Ago | 0.11 | 0.30 | 0.49 | 0.87 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (6/2022) |
Next Qtr (9/2022) |
Current Year (12/2022) |
Next Year (12/2023) |
|
---|---|---|---|---|
Most Accurate Estimate | 0.09 | 0.31 | -0.08 | -0.09 |
Zacks Consensus Estimate | 0.08 | 0.23 | 0.06 | 0.26 |
Earnings ESP | 2.00% | 37.78% | -233.33% | -134.62% |
Surprise - Reported Earnings History
Quarter Ending (3/2022) |
Quarter Ending (12/2021) |
Quarter Ending (9/2021) |
Quarter Ending (6/2021) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -0.24 | -0.43 | -0.48 | -0.80 | NA |
Estimate | -0.12 | -0.30 | -0.60 | -0.96 | NA |
Difference | -0.12 | -0.13 | 0.12 | 0.16 | 0.01 |
Surprise | -100.00% | -43.33% | 20.00% | 16.67% | -26.67% |
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more